New Generation of 3D Virtual Models with Perfusional Zones: Perioperative Assistance for the Best Pedicle Management during Robotic Partial Nephrectomy.

Journal: Current oncology (Toronto, Ont.)
PMID:

Abstract

Selective clamping during robot-assisted partial nephrectomy (RAPN) may reduce ischemia-related functional impairment. The intraoperative use of 3D-virtual models (3DVMs) can improve surgical planning, resulting in a greater success rate for selective clamping. Our goal is to introduce a new generation of 3DVMs, which consider the perfusion volumes of the kidney. Patients listed for RAPN from 2021 to 2022 were recruited. A selective clamping strategy was designed and intraoperatively performed based on the specifically generated 3DVMs. The effectiveness of selective clamping was evaluated using near-infrared-fluorescence imaging (NIRF) and 3DVM. Perfusion areas extensions were compared, and relevant preoperative characteristics were analyzed. In 61 of 80 (76.25%) cases, selective clamping was performed. The concordance between the 3DVM areas and the NIRF-enhanced areas was verified (k = 0.91). According to the distribution of perfused areas crossing the tumor, there were one, two, three, four, and five crossing areas, with relative perfusion rates of 13.75%, 35%, 32.5%, 13.75%, and 5%, respectively. Lesion diameter and mesorenal location were the only factors related to a higher number (>3) of perfusion volumes crossing the lesion. The implementation of mathematical algorithms to 3DVMs allows for precise estimation of the perfusion zone of each arterial branch feeding the organ, leading to the performance of safe and effective pedicle management planning.

Authors

  • Daniele Amparore
    Division of Urology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
  • Federico Piramide
    Department of Urology, "San Luigi Gonzaga" Hospital, University of Turin, Orbassano (Turin), Italy.
  • Paolo Verri
    Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (Turin), Italy.
  • Enrico Checcucci
    Division of Urology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
  • Sabrina De Cillis
    Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
  • Alberto Piana
    Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
  • Gabriele Volpi
    Department of Urology, "San Luigi Gonzaga" Hospital, University of Turin, Orbassano (Turin), Italy.
  • Mariano Burgio
    Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Regione Gonzole 10, 10043, Orbassano (Turin), Italy.
  • Giovanni Busacca
    Department of Urology, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy.
  • Marco Colombo
    Department of Urology, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy.
  • Cristian Fiori
    Division of Urology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
  • Francesco Porpiglia
    Division of Urology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.